Compass Therapeutics (NASDAQ:CMPX) Lowered to Hold Rating by Leerink Partnrs

Leerink Partnrs downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a strong-buy rating to a hold rating in a research report report published on Friday morning,Zacks.com reports.

Other analysts also recently issued reports about the stock. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Friday. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. Wedbush restated an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Compass Therapeutics Trading Down 13.2 %

CMPX traded down $0.21 during trading on Friday, reaching $1.38. 1,348,934 shares of the company were exchanged, compared to its average volume of 438,274. The stock has a market cap of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.34. The firm has a 50 day moving average of $1.75 and a 200 day moving average of $1.42.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, analysts forecast that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently modified their holdings of the stock. Opaleye Management Inc. purchased a new stake in shares of Compass Therapeutics during the first quarter valued at $6,277,000. CM Management LLC lifted its stake in Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after buying an additional 185,000 shares in the last quarter. Ground Swell Capital LLC purchased a new stake in Compass Therapeutics during the second quarter valued at about $124,000. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Compass Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after acquiring an additional 71,008 shares in the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.